Azure Health Technology completes study protocol for Pancreatic Cancer Phase II clinical study

Glenn Tong Glenn Tong

Glenn Tong

Chief Executive Officer and Managing Director at VGI Health Technology Limited (NSX:VTL)

发布日期: 2020年9月21日
+ 关注
No alt text provided for this image

Sydney, Australia 21 September 2020 – Azure Health Technology Limited (AZT) today announced that it has completed the preparation of a study protocol for a Phase II clinical study on Pancreatic Adenocarcinoma (Pancreatic Cancer) and has received supportive feedback from Key Opinion Leaders (KOLs).  See link for press release with details and what cancer expert Professor Richard Pestell AO has to say about this clinical study.


Kate Lingard

4 年

Congratulations, this always an exciting time.

赞
回复
Glenn Tong

Chief Executive Officer and Managing Director at VGI Health Technology Limited (NSX:VTL)

4 年

Thank you Anthony....the Azure Health team is very excited about moving this important program forward and getting great support from Key Opinion Leaders in cancer research

赞
回复
Anthony Thompson

Corporate Advisor at Novus Capital Limited

4 年

Well done Azure Health Technology!

赞
回复
查看更多评论

要查看或添加评论，请登录

Glenn Tong的更多文章

社区洞察

其他会员也浏览了